Colostrinin Distribution in Poland
June 02 2009 - 7:50AM
UK Regulatory
TIDMRGT
RNS Number : 2090T
ReGen Therapeutics PLC
02 June 2009
2/06/2009
For immediate release
AIM/PLUS: RGT
ReGen Signs Exclusive Distribution Agreement for Colostrinin(TM) in Poland
ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that it has today
signed an agreement with Tagerr Polska* for the exclusive distribution and
marketing of its nutritional supplement Colostrinin(TM) in Poland. This comes
after a period of test - marketing by Tagerr during which Tagerr also satisfied
all necessary regulatory requirements to import/distribute the product in
Poland. To date Colostrinin(TM) is marketed in the US, Canada and Australia
under the brand name CogniSure(TM) ** and in Cyprus under the brand name
Cognase(TM) *** as a nutritional supplement to 'support healthy brain ageing and
cognition in humans'.
Commenting on this agreement Percy Lomax, Chairman and Chief Executive Officer
of ReGen said :
'Poland is the country where Colostrinin(TM) was first discovered and we know
from various communications that there is significant knowledge of the product
in Poland. Poland has a population of 38 million people and a Gross Domestic
Product per Capita of $11,072. As such both Tagerr Polska and ourselves are
optimistic that the volume of sales here should be significant.'
*Tagerr Polska is an affliate of Tagerr a professional services and trading
company established in Köln, Germany. In operation since 1995, Tagerr has
enjoyed considerable successes in marketing and distributing consumer products,
including food supplements, in central Europe and Germany. (www.cognisure.eu)
**Colostrinin(TM) for use as a human nutraceutical is licensed in North America
and Australasia to Metagenics Inc. of San Clemente, California
(www.metagenics.com).
*** Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi
Pharmaceuticals Ltd (www.healthybrainaging.com)
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628
3396
Nick Bealer/David Scott
Alexander David
Tel No 020 7448 9820
Notes to Editors:
Colostrinin(TM) is derived from colostrum a mammal's first milk after birth and
is produced in a production line in S Dakota, freeze dried in Oregon and
tabletted at Metagenics Inc plant in California. Metagenics are the distributors
in North America and Australia. If full production and sales were achieved on
North American margins revenue to the Company would be $10 million before
relatively low head office expenses. It would be possible, by spending around
another $550,000 to bring production facilities up to a level to generate
revenue of around $50 million.
Colostrinin(TM) has been available in the professional channel of the healthcare
market in North America and Australia for over a year. Although achieving
professional awareness and endorsement was a necessary first step, retail
distribution, was always and remains our objective.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCCKBKQDBKDOAK
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Apr 2023 to Apr 2024